Arqule (ARQL) Updates on Tivantinib Combo Phase 2 in MET-High, KRAS Wild-Type Metastatic CRC
Tweet Send to a Friend
Arqule (Nasdaq: ARQL) announced interim data from an ongoing investigator-initiated Phase 2 clinical trial with tivantinib in combination with cetuximab ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
